BridgeBio Oncology (BBOT) awards stock options and RSUs to chief medical officer

Rhea-AI Filing Summary

BridgeBio Oncology Therapeutics, Inc. reported that Chief Medical & Development Officer Ben Yong received new equity awards on March 10, 2026. He was granted a stock option for 210,000 shares of Common Stock at an exercise price of $10.19 per share, expiring in 2036.

He also received 46,670 restricted stock units (RSUs), each representing one share of Common Stock. The RSUs vest in 16 equal quarterly installments over four years from January 1, 2026, and the option vests in 48 substantially equal monthly installments from the same date, in each case contingent on continued service.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Ben Yong

Role Chief Med & Dev Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	210,000	$0.00	--
Grant/Award	Common Stock	46,670	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 210,000 shares (Direct); Common Stock — 46,670 shares (Direct)

Footnotes (1)

1. Represents a grant of restricted stock units ("RSUs"), each representing a contingent right to receive one share of the Issuer's Common Stock. The RSUs vest in 16 equal quarterly installments over a period of four years from January 1, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. The RSUs will be settled in shares of Common Stock upon vesting. 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of January 1, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ben Yong

(Last) (First) (Middle)

BRIDGEBIO ONCOLOGY THERAPEUTICS, INC.

256 EAST GRAND AVENUE, SUITE 104

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Oncology Therapeutics, Inc. [ BBOT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Med & Dev Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/10/2026		A		46,670(1)	A	$0	46,670	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$10.19	03/10/2026		A		210,000		(2)	03/09/2036	Common Stock	210,000	$0	210,000	D

Explanation of Responses:

1. Represents a grant of restricted stock units ("RSUs"), each representing a contingent right to receive one share of the Issuer's Common Stock. The RSUs vest in 16 equal quarterly installments over a period of four years from January 1, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. The RSUs will be settled in shares of Common Stock upon vesting.

2. 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of January 1, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.

	/s/ Uneek Mehra, Attorney-in-Fact	03/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did BridgeBio Oncology Therapeutics (BBOT) disclose for Ben Yong?

BridgeBio Oncology disclosed that Chief Medical & Development Officer Ben Yong received new equity awards. He was granted 210,000 stock options and 46,670 restricted stock units as compensation, rather than buying shares in the open market, with vesting tied to continued service.

How many stock options did Ben Yong receive from BridgeBio Oncology (BBOT) and at what price?

Ben Yong received a grant of stock options covering 210,000 shares of BridgeBio Oncology common stock. These options have an exercise price of $10.19 per share and expire in 2036, providing long-term equity-based compensation if he remains with the company.

What restricted stock unit (RSU) grant did BridgeBio Oncology (BBOT) make to Ben Yong?

BridgeBio Oncology granted Ben Yong 46,670 restricted stock units, each equal to one share of common stock. The RSUs vest in 16 equal quarterly installments over four years from January 1, 2026, and are settled in shares upon vesting, subject to continued service.

How do the stock options granted to Ben Yong at BridgeBio Oncology (BBOT) vest?

The 210,000 stock options granted to Ben Yong vest over four years. One forty-eighth of the option shares vest and become exercisable in substantially equal monthly installments on each monthly anniversary of January 1, 2026, conditioned on his continued service.

Did Ben Yong buy or sell BridgeBio Oncology (BBOT) shares in the market?

The Form 4 shows equity awards, not market trades. Ben Yong acquired 210,000 options and 46,670 RSUs at a price of $0.00 per share as compensation grants, rather than purchasing or selling shares on the open market.

What are Ben Yong’s direct holdings after these BridgeBio Oncology (BBOT) grants?

Following these transactions, Ben Yong directly holds 46,670 shares of BridgeBio Oncology common stock and a stock option covering 210,000 underlying shares. These positions reflect his compensation awards as reported, tied to multi-year vesting schedules requiring continued service.